DIA 2024 Global Annual Meeting Welcomes Life Sciences Leaders to Confront Emerging Challenges in Healthcare

DIA 2024 Global Annual Meeting Welcomes Life Sciences Leaders to Confront Emerging Challenges in Healthcare

DIA 2024 Global Annual Meeting Welcomes Life Sciences Leaders to Confront Emerging Challenges in Healthcare

Registration open for world’s preeminent industry-neutral forum tackling AI, advanced therapies, and regulatory obstacles

WASHINGTON–(BUSINESS WIRE)–#DIA–The ethical use of artificial intelligence (AI) in healthcare, the development of advanced therapies, and other emerging regulatory and scientific challenges demand in-depth discussion as DIA, a global organization of life sciences professionals, accepts registrations for the DIA 2024 Global Annual Meeting, to be held June 16-20 in San Diego.

Thousands of industry representatives, regulators, government officials, academics, innovators, and patients will convene for the world’s preeminent neutral life sciences forum — and the only thing missing is you. Advance registration is open until April 12, and media members are encouraged to attend.

“This year marks the 60th anniversary of DIA and the Global Annual Meeting, and we’re celebrating by continuing to forge a bold future marked by innovation and impact,” said Marwan Fathallah, DIA’s President and Global Chief Executive. “That drive is reflected in this year’s theme, ‘Charting new horizons,’ which reflects the need to adjust our mindsets and come together to benefit patients everywhere.”

With 220 sessions and more than 500 speakers across 13 engaging content tracks, the event allows attendees to explore the depths of their field, discover new topics of interest, network, and have conversations that don’t happen anywhere else.

They’ll hear from top executives, scientific minds, regulators, academics, and patient advocates from across the ecosystem, including representatives from Amgen, Bayer, Eli Lilly, GSK, IQVIA, Johnson & Johnson, Merck & Co., Microsoft Research, Novartis, Parexel, Pfizer, and Sanofi. Presenters will discuss AI, decentralized clinical trials (DCT), pharmacovigilance, drug development, precision medicine, and diversity, equity, and inclusion (DEI).

In addition, the much-anticipated “DIAmond sessions” will include:

— “Navigating the Trusted, Responsible, and Ethical Horizon of Artificial Intelligence: Uniting Healthcare Perspectives,” which explores responsible AI use from diverse stakeholders’ perspectives.

— “Combination Products: Advanced Drug Delivery Technologies and Cell/Gene Therapies,” which addresses how advanced therapies may provide cures for untreatable conditions.

— An interactive forum featuring U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) representatives discussing today’s regulatory, scientific, and communication challenges.

Attendees are invited aboard the USS Midway on June 16 for an unforgettable reception celebrating DIA’s 60th anniversary.

Standard rates go into effect April 13 until May 15, though late registrations are available. Students, patient advocates, independent contractors, and groups receive reduced rates.

To register or view the event program, visit https://www.diaglobal.org/en/flagship/dia-2024. Media members can request credentials by emailing diaglobal@gregoryfca.com.

About DIA

DIA is a leading global life science membership association that drives collaboration in drug, device, and diagnostics development in pursuit of a healthier world. Founded in 1964 with headquarters in Washington, D.C., and offices in Europe and Asia, DIA provides unparalleled networking opportunities, educational resources, scientific research publications, and professional development programs to members in more than 80 countries.

Learn more at DIAglobal.org, and connect with DIA on LinkedIn, Facebook, X (Twitter), and Instagram.


Denise DiMeglio

Gregory FCA